b thalassaemia major is one of the most severe forms of anaemia.
ent anaemias, lead the PDCO to expand the request for additional data to the cited patients populations. The DEEP Project has been developed with the specific intent to integrate the existing information on deferiprone use in children aged 2-10 years old, thus covering the lack of knowledge and providing a valid support to the use of the drug in this age group. According to the recent scientific advancements and the opinion expressed by the PDCO, the project has been expanded to include the whole paediatric population and other chronic transfusion dependent anaemias. The aim of this application is to provide data on pharmacokinetics and comparative efficacy/safety of deferiprone, in order to produce an approved Paediatric Investigational Plan to be used for regulatory purposes. The trial is multicentric, open label and non-inferiority active-controlled. There are 12 participating centres from 9 different countries, including industry (Italy, UK, The Netherlands, Tunisia, Greece, Cyprus, Egypt and Canada). At the end of the proposed set of studies, deferiprone, will be available at efficacious dosages in children <18 years as first line treatment. In addition, a three year safety study will evaluate all deferiprone uses in the clinical setting. ©Copyright E. Missouri-Khetab, 2013 Licensee PAGEPress, Italy Thalassemia Reports 2013 3(s1):e38 doi:10.4081/thal.2013.s1.e38 This 
